Profiles Header - Harvard Catalyst Profiles Header – Harvard Catalyst

Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Reed Francis Beall, Ph.D.

Title
Institution
Department
Address

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Darrow JJ, Beall RF, Kesselheim AS. The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents. Appl Health Econ Health Policy. 2018 Aug 24. PMID: 30141133.
    View in: PubMed
  2. Beall RF, Darrow JJ, Kesselheim AS. Patent term restoration for top-selling drugs in the United States. Drug Discov Today. 2018 Jul 25. PMID: 30055271.
    View in: PubMed
  3. Sarpatwari A, Beall RF, Abdurrob A, He M, Kesselheim AS. Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period. Health Aff (Millwood). 2018 05; 37(5):732-737. PMID: 29733729.
    View in: PubMed
  4. Beall RF, Kesselheim AS. Tertiary patenting on drug-device combination products in the United States. Nat Biotechnol. 2018 Feb 06; 36(2):142-145. PMID: 29406508.
    View in: PubMed
  5. Darrow JJ, Beall RF, Kesselheim AS. Will inter partes review speed US generic drug entry? Nat Biotechnol. 2017 Dec 08; 35(12):1139-1141. PMID: 29220017.
    View in: PubMed
  6. Beall RF, Blanchet R, Attaran A. In which developing countries are patents on essential medicines being filed? Global Health. 2017 06 26; 13(1):38. PMID: 28651631.
    View in: PubMed
  7. Beall RF, Attaran A. A method for understanding generic procurement of HIV medicines by developing countries with patent protection. Soc Sci Med. 2017 07; 185:118-126. PMID: 28578209.
    View in: PubMed
  8. Beall RF, Attaran A. Which patent and where? Why international patent transparency by companies is needed for medicines. Nat Biotechnol. 2016 09 08; 34(9):923-6. PMID: 27606455.
    View in: PubMed
  9. Beall RF, Schwalm JD, Huffman MD, McCready T, Yusuf S, Attaran A. Could patents interfere with the development of a cardiovascular polypill? J Transl Med. 2016 08 18; 14(1):242. PMID: 27538505; PMCID: PMC4991009.
  10. Kaplan WA, Beall RF. The global intellectual property ecosystem for insulin and its public health implications: an observational study. J Pharm Policy Pract. 2017; 10:3. PMID: 27446593; PMCID: PMC4955122.
  11. Houston AR, Beall RF, Attaran A. Upstream solutions for price-gouging on critical generic medicines. J Pharm Policy Pract. 2016; 9:15. PMID: 27141308; PMCID: PMC4852412.
  12. Attaran A, Mackey T, Beall R. Lowering the High Cost of Cancer Drugs--III. Mayo Clin Proc. 2016 Mar; 91(3):399-400. PMID: 26944246.
    View in: PubMed
  13. Beall RF, Nickerson JW, Kaplan WA, Attaran A. Is Patent "Evergreening" Restricting Access to Medicine/Device Combination Products? PLoS One. 2016; 11(2):e0148939. PMID: 26910128; PMCID: PMC4766186.
  14. Beall RF, Attaran A, Kuhn R. Compulsory Licenses: The Authors Reply. Health Aff (Millwood). 2015 Jun; 34(6):1068. PMID: 26056220.
    View in: PubMed
  15. Beall RF, Kuhn R, Attaran A. Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurement. Health Aff (Millwood). 2015 Mar; 34(3):493-501. PMID: 25732501.
    View in: PubMed
  16. Golfam M, Beall R, Brehaut J, Saeed S, Relton C, Ashbury FD, Little J. Comparing alternative design options for chronic disease prevention interventions. Eur J Clin Invest. 2015 Jan; 45(1):87-99. PMID: 25388015.
    View in: PubMed
  17. Beall RF, Nickerson JW, Attaran A. Pan-Canadian overpricing of medicines: a 6-country study of cost control for generic medicines. Open Med. 2014; 8(4):e130-5. PMID: 25426181; PMCID: PMC4242790.
  18. Saeed S, Golfam M, Beall RF, Ashbury FD, Palmer LJ, Little J. Effectiveness of individual-focused interventions to prevent chronic disease. Eur J Clin Invest. 2014 Sep; 44(9):883-91. PMID: 25041535.
    View in: PubMed
  19. Beall RF, Baskerville N, Golfam M, Saeed S, Little J. Modes of delivery in preventive intervention studies: a rapid review. Eur J Clin Invest. 2014 Jul; 44(7):688-96. PMID: 24828885.
    View in: PubMed
  20. Kuhn R, Beall RF. The time for pharmaceutical compulsory licensing has expired. Nat Med. 2012 Aug; 18(8):1168. PMID: 22869177.
    View in: PubMed
  21. Beall R, Kuhn R. Trends in compulsory licensing of pharmaceuticals since the Doha Declaration: a database analysis. PLoS Med. 2012 Jan; 9(1):e1001154. PMID: 22253577; PMCID: PMC3254665.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Beall's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (65)
Explore
_
Co-Authors (3)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Tool Page Footer - Harvard Catalyst Tool Page Footer – Harvard Catalyst
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.